GONORRHEA remains the most frequently reported infectious disease in the United States. Antimicrobial resistance in the gonococcus continues to evolve, and coinfection with Chlamydia trachomatis is a serious problem. Therefore, the periodic review of current therapies for gonorrhea to ensure effective treatment must be a major objective of the National Gonorrhea Control Program in the United States.
In the past five years, the number of potentially useful antimicrobial agents for the treatment of gonococcal infections has proliferated: these include second- and third-generation cephalosporins, regimens combining the β-lactamase inhibitors clavulanic acid and sulbactam with penicillin and amoxicillin, and the quinolones.
This article reviews (1) recent trends in gonococcal antimicrobial resistance and in vitro susceptibility to established and experimental regimens; (2) coinfection due to C trachomatis and Neisseria gonorrhoeae within the past five years; (3) therapy for incubating syphilis and gonorrhea; (4) prophylaxis of sexual partners exposed to resistant organisms; and (5)
Rice RJ, Thompson SE. Treatment of Uncomplicated Infections due to Neisseria gonorrhoeaeA Review of Clinical Efficacy and In Vitro Susceptibility Studies From 1982 Through 1985. JAMA. 1986;255(13):1739–1746. doi:10.1001/jama.1986.03370130095031